Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors |
| |
Authors: | Kamata Junichi Okada Toshimi Kotake Yoshihiko Niijima Jun Nakamura Katsuji Uenaka Toshimitsu Yamaguchi Atsumi Tsukahara Kappei Nagasu Takeshi Koyanagi Nozomu Kitoh Kyosuke Yoshimatsu Kentaro Yoshino Hiroshi Sugumi Hiroyuki |
| |
Affiliation: | Tsukuba Research Laboratories, Eisai Co. Ltd., Tsukuba, Ibaraki 300-2635, Japan. j-kamata@hhc.eisai.co.jp |
| |
Abstract: | As part of a series of studies to discover new topoisomerase II inhibitors, novel pyrimidoacridones, pyrimidophenoxadines, and pyrimidocarbazoles were synthesized, and in vitro and in vivo antitumor activities and DNA-protein and/or DNA-topoisomerase II cross-linking activity as an indicator of topoisomerase II-DNA cleavable complex formation were evaluated. The pyrimidocarbazoles possessed high in vitro and in vivo potencies. Compound 26 (ER-37326), 8-acetyl-2-[2-(dimethylamino)ethyl]-1H-pyrimido[5,6,1-jk]carbazole-1,3(2H)-dione, showed in vitro growth inhibitory activity with respective IC(50) values of 0.049 microM and 0.35 microM against mouse leukemia P388 and human oral cancer KB. In vivo, this compound inhibited the tumor growth of mouse sarcoma M5076 implanted into mice with T/C values of 42% and 13% at 3.13 and 6.25 mg/kg/d respectively without significantly affecting the body weight. In addition, compound 26 (ER-37326) increased the formation of DNA-topoisomerase II cross-linking in P388 cells. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|